natgillin/translations-raw huggingface dataset:
The use of a compound according to any one of claims 1-14 for the preparation of medicaments for the therapeutic and/or prophylactic treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders, schizophrenia, neurological diseases, Parkinson's disease, neurodegenerative disorders, Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse, metabolic disorders, eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders. 
Uporaba spoja prema bilo kojem od zahtjeva 1 do 14, naznačena time, da je za proizvodnju lijeka za terapeutsko i/ili profilaktičko liječenje sljedećih poremećaja: depresija, anksioznost, bipolarni poremećaj, poremećaj nedostatka pažnje i hiperaktivnosti (ADHD), poremećaji povezani sa stresom, psihotički poremećaji, shizofrenija, neurološke bolesti, Parkinsonova bolest, neurodegenerativni poremećaji, Alzheimerova bolest, epilepsija, migrena, hipertenzija, zlouporaba droga, metabolički poremećaji, poremećaji hranjenja, dijabetes, komplikacije kod dijabetesa, pretilost, dislipidemija, poremećaji kod potrošnje energije i asimilacije, poremećaji i nepravilnosti u funkciji homeostaze tjelesne temperature, poremećaji spavanja 1 srčanog ritma, 1 kardiovaskularni poremećaji.
A radiation curable gel nail coating composition according to claim 6, wherein the plasticizer is selected from sucrose acetate isobutyrate, ethyl tosylamide, and camphor, or a mixture thereof. 
Pripravak u vidu gel-laka za nokte za čije sušenje se korisiti zračenje prema patentnom zahtjevu 6, naznačen time, što je plastifikator izabran iz grupe koju čine acetat izobutirat saharoza, etil tozilamid, kamfor i njihove smjese.
An article of manufacture for human pharmaceutical or diagnostic use, comprising packaging material and a container comprising a solution or a lyophilized form of the protein scaffold of any one of claims 1-3, wherein said container optionally is a component of a parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracerebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, intralesional, bolus, vaginal, rectal, buccal, sublingual, intranasal, or transdermal delivery device or system. 
14. Predmet proizvodnje za ljudsku, farmaceutsku ili dijagnostičku upotrebu, koji sadrži materijal za pakiranje i posudu koja sadrži otopinu ili liofilizirani oblik proteinske platforme prema bilo kojem od patentnih zahtjeva 1 do 3, pri čemu je opcionalno navedena posuda komponenta parenteralnog, subkutanog, intramuskularnog, intravenoznog, intraartikularnog, intrabronhialnog, intraabdominalnog, intrakapsularnog, intrakartilaginoznog, intrakavitalnog, intracelularnog, intracerebelarnog, intracerebroventrikularnog, intrakoličnog, intracervikalnog, intragastičnog, intrahepatičnog, intramiokardialnog, intraostealnog, intrapelvičnog, intraperikardijalnog, intraperitonealnog, intrapleuralnog, intraprostatičnog, intrapulmonarnog, intrarektalnog, intrarenalnog, intraretinalnog, intraspinalnog,
the carbocyclyl and heterocyclyl portions of such substituents optionally are substituted with one or two substituents independently selected from the group consisting of alkyl, carboxy, hydroxy, alkyloxy, halo, nitro, cyano, and amino. 
(1) karbociklil dio od karbociklilalkila i heterociklil dio od heterociklilalkila po izboru su supstituirani jednim ili više supstituenata neovisno odabranima iz skupine koja sadrži alkil, alkenil, alkinil, karboksi, hidroksi, alkiloksi, alkeniloksi, alkiniloksi, halo, nitro, cijano, azido, okso i amino, i
The compound or a salt thereof, for use in the treatment of a chronic hyperkinetic movement disorder. 
D Bi D ili njegova sol, naznačen time da je za uporabu za liječenje kroničnog poremećaja hiperkinetičkog pokreta.
Compounds according to Claim 1, selected from the group 
Spojevi prema zahtjevu 1, naznačeni time da su odabrani iz skupine koja sadrži
A candle holder arrangement as claimed in claim 1 or 2 wherein the inward most point of the tapered portion (16c) of the sides (16) defines a single aperture (15). 
Aranžman sa svijećnjakom sukladno Zahtjevu 1 ili 2 pri čemu je najuži dio suženog dijela (16c) stranica (16) određuje jedini otvor (15).
Certain novel intermediates utilised in the above processes are provided as a further feature of the present invention together with the process for their preparation. 
Određeni novi intermedijeri korišteni u gornjim postupcima navedeni su kao dodatna značajka ovog izuma, zajedno sa postupcima za njihovu pripravu.
a compound having the formula (I): and/or a compound having the formula (II): and 
spoj s formulom (I): [image] i/ili spoj s formulom (II):
Detailed description of preferred embodiments of the invention 
Datum objave europske prijave patenta:
In the practice of the method, mammal in need thereof will preferably have one or more defects, deficiencies, or a substantial or total absence of functional, biologically-active retGC1 protein in one or more tissues within or about the body of the mammal, when compared to the level of biologically-active retGC1 protein in a normal mammal. 
Vektor ili pripravak za uporabu prema zahtjevu 15, naznačen time što sisavac kojem je to potrebno ima defekt, nedostatak 1li značajnu odsutnost biološki aktivnog proteina retGC1 barem u prvom tkivu sisavca, u usporedbi s razinom biološki aktivnog proteina retGC1 kod normalnog sisavca.
at least one clock suitable for providing time and date data; 
- barem jedan sat (103) pogodan za dobivanje podataka o vremenskim oznakama;
reacting the AvPAL variant with NHS-activated polyethylene glycol at a ratio of 3 polyethylene glycol per lysine residue of AvPAL variant. The AvPAL variant of claim 15, wherein at least 28 percent of lysine residues at positions 2, 10, 32, 145, 195, 301, 413, 493, and 522 of the AvPAL variant are pegylated; 
AvPAL varijanta u skladu s patentnim zahtjevom 17, naznačena time, da je barem 28 & lizinskih ostataka na položajima 2, 10, 32, 145, 195, 301, 413, 493 te 522 AvPAL varijante pegilirano, pri čemu je barem 51 % lizinskih ostataka pegilirano na položajima 2, 10, 195, 413, 493 te 522 AvPAL varijante ili pri čemu je najmanje 75 % lizinskih ostataka pegilirano na položajima 2, 10, 195, 493 i 522 AvPAL varijante.
The process according to any one of claims 22 to 25, wherein the reacting of the compound of Formula VI and the compound of Formula X, or salt thereof, are conducted in a solvent component comprising dichloromethane. 
Postupak prema bilo kojim od zahtjeva 1 do 13, naznačen time što se reakcija 2-(3-(4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il)azetidin-3-il)acetonitril dihidrokloridne soli sa spojem Formule VI provodi u otapalu koje se sastoji od diklormetana.
As a result of such exposure milk lipid oxidation products such as pentanal and hexanal, and dimethylsulphide are formed. 
Kao rezultat takvog izlaganja, stvaraju se produkti oksidacije mliječnih lipida, kao npr. pentanal i heksanal, i dimetilsulfid.
Use of (a) compound of the formula [I] of claim 1 or a pharmaceutically acceptable salt thereof as an active ingredient and (b) at least one other antitumor compound, in combination, for the production of an antitumor agent. 
Upotreba (a) spoja formule [I] u skladu s patentnim zahtjevom 24, ili njegove farmaceutski prihvatljive soli, kao aktivnog sastojka i (b) najmanje još jednog antitumorskog spoja, u kombinaciji, naznačena time što su spoj formule [I] i dodatni antitumorski spoj namijenjeni proizvodnji antitumorskog sredstva.
A method for the production of a metabolization product, wherein said method utilizes a cell according to claim 5 and wherein the metabolization product is selected from lactic acid, acetic acid, succinic acid, malic acid, 1-butanol, isobutanol, 2-butanol, other alcohols, amino acids, 1,3-propanediol, ethylene, glycerol, a B-lactam antibiotic or a cephalosporin, alkanes, terpenes, isoprenoids and the precursor molecule amorphadiene of the antimalarial drug artemisinin. 
Uporaba stanice u skladu s bilo kojim od patentnih zahtjeva 6 do 9 za pretvorbu i metabolizam, posebno fermentaciju, biomaterijala koji sadrži ksilozu i/ili stvaranje produkta metabolizma, pri čemu je produkt metabolizma poželjno odabran iz grupe kemikalija na temelju biobaza, kao što je mliječna kiselina, octena kiselina, jantarna kiselina, maleinska kiselina, 1-butanol, izobutanol, 2-butanol, drugi alkoholi, aminokiseline, 1,3-propandiol, etilen, glicerol, B-laktamski antibiotik ili cefalosporin, alkani, terpeni, izoprenoidi ili prekursorska molekula amorfadiena iz antimalarijski aktivnog sastojka artemizinina.
is phenyl substituted or unsubstituted with one or two Ra members and substituted in the ortho position with Rb; Ra is halo, C1-4alkyl, or C1-4alkoxy; Rb is triazole or pyrimidine substituted or unsubstituted with halo or C1-4alkyl; 
je fenil supstituiran ili nesupstituiran sa jednim ili dva Račlanovai supstituiran u orto položaju sa Rb; Ra je halo, C1-4alkil, ili C1-4alkoksi; Rb je triazol ili pirimidin supstituiran ili nesupstituiran sa halo ili C1-4alkil;
a sensor member for detecting when a user's finger or another body comes into contact with a touch zone; and a control for controlling the electrical apparatus according to a specific function following detection of a contact of the user's finger or another body with the touch zone, 
* - senzorički element (130), prilagođen za detektiranje kada korisnikov prst ili drugo tijelo dođe u kontakt s dodirnom zonom (T) navedene pokrivne površine (110),
each Yi is a beta-aggregating sequence independently selected from 6 to 16 contiguous amino acids, at least 50% of which are hydrophobic amino acids, and in which at least one aliphatic residue or F is present, and if only one aliphatic residue or F is present, at least one, and preferably at least two, other residues are selected from Y, W, A, M and T; and in which no more than 1, and preferably none, P, R, K, D or E residue is present, and wherein at least one Yi is a stretch identical to or differing with no more than one amino acid substitution from a contiguous stretch of amino acids naturally occurring in the protein identified in step a); and 
- svaki Y; je beta-agregacijska sekvenca neovisno odabrana između 6 do 16 susjednih aminokiselina od kojih je barem 50% hidrofobnih aminokiselina i u kojima je prisutan najmanje jedan alifatski ostatak ili F, i ako je je prisutan najmanje jedan alifatski ostatak ili F, najmanje jedan, a poželjno najmanje dva od ostalih ostataka odabrani su od Y, W, A, M i T; i u kojem nije prisutan više od 1, a poželjno ni jedan P, R, K, Dili E ostatak, 1 pri čemu je barem jedan Yi slijed identičan ili različit od ne više od jedne supstitucije aminokiselina iz susjednog proteina aminokiselina koje se prirodno pojavljuju u proteinu identificiranom u koraku a); i -
A method for manufacturing 4-((1R,3S)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine (formula I) or a salt thereof, which method comprises converting the compound of formula Va to the compound of formula I, wherein formula I and Va are as follows: 
Postupak proizvodnje 4-((1R,3S)-6-klor-3-fenilmdan-1-i11)-1,2,2-trimetilpiperazina (formula I) ili njegove soli, a postupak obuhvaća pretvorbu spoja formule Va cis-konfiguracije u spoj formule 1, gdje su formula I i Va kako slijedi:
Fig. 4 shows the state in which the bell member 9 and the capsule holder 13 are brought in closing pressure engagement and due to the water entering the interior of the capsule and building up a pressure there the pyramidal relief members 12 of the capsule holder 13 have already produced openings in the foil member 5 of the capsule 1. 
Slika 4 prikazuje položaj u kojemu su zvonasti element 9 i držač čahure 13 stavljeni u položaj kada su zatvoreni pod pritiskom 1 zbog toga što je voda koja je ušla u unutrašnjost čahure i povisila tlak, reljefni elementi 12 držača čahure 13, koji imaju oblik piramida, stvorili su otvore na elementu od folije 5 čahure 1.
H CH2CH2SCH3 The composition according to any of the preceding claims, wherein the one or more additional active agent is selected from the group consisting of an arylpyrazole, a neonicotinoid, a pyrethroid, an amino acetonitrile compound, a paraherquamide, a spinosyn active, a cyclic depsipeptide, a benzimidazole active, an imidazothiazole active, a tetrahydropyrimidine active, praziquantel, an avermectin, a milbemycin and an insect growth regulator. 
Veterinarski ili agrikulturni sastav prema zahtjevu 24, naznačen time, da je antitrematodno sredstvo odabrano iz skupine koja se sastoji od sljedećih: miracil D, mirasan, prazikvantel, klonazepam, meklonazepam, oltipraz, lukanton, hikanton, oksamnikin, amoskanat, niridazol, nitroksibil, heksaklorofen, bitionol, bitionol-sulfoksid, meniklofolan, = tribromsalan, = oksiklonazid, klioksanid, rafoksanid, = brotianid, -bromoksanid, = klozantel, triklabendazol, diamfenetid, klorsulon, hetolin i emetin.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidenebenzonorbornene-5-yl)amide and as component (B) chlorothalonil. 
Pripravak prema zahtjevu 1, naznačen time da sadrži kao komponentu (A) spoj 3-difluorometil-1-metil-1Hpirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-il)amid, a kao komponentu (B) fludioksonil.
in which the downward oriented speed vectors at proximity of the of the vertical central axis of revolution show a downward speed component up to 2 m/s. 
6.8 gdje prema dolje usmjereni vektori brzine u blizini okomite središnje osi vrtnje imaju prema dolje usmjerenu komponentu brzine do 2 m/s;
After separation of the layers, the aq. phase was extracted 2x with EtOAc. 
Poslije razdvajanja slojeva, vodena faza je esktrahirana 2x sa EtOAc.
The overall length was 84 mm. 
Ukupna dužina bila je 84 mm.
The device according to claim 11, wherein said conveyor belt is configured to load the fine screen with the fine-particle excavation material, and wherein fine-particle or finest-particle material separated from the excavation material is used at least in part instead of separately supplied cable sand, or said material is additionally used for embedding and surrounding the device being inserted in the cable trench. 
Uređaj prema zahtjevu 6, naznačen time, da se fino sito može isporučiti s iskopanim sitnim česticama (Kmf) pomoću transportne trake (56) i da se tamo odvoji materijal za sitne čestice rova, posebno fin ili ultrafini materijal u obliku pijeska s finim česticama u obliku pijeska, može se upotrijebiti za nadopunu odvojeno isporučenog pijeska kabela ili sličnog barem djelomično za ugradnju i ponovno pohranjivanje kabela i/ili vodova (L) postavljenog kabelskog kanala (K).
A method for preparing Montelukast acid of formula 1 or the sodium salt thereof, comprising 
Postupak dobivanja Montelukastove kiseline formule 1 ili njezine natrijeve soli, naznačen time što se sastoji u koraku kondenziranja tiolnog spoja formule 2
The tubular member comprises reinforcement ribs 18 extending on its outer surface. 
Cijevni element ima rebra za pojačanje 18 koja se prostiru po njegovoj vanjskoj površini.
The control system (1) of claim 7, wherein said coupling pin (32) has a polygonal, preferably square section. 
Kontrolni sustav (1) prema zahtjevu 7, naznačen time da spojni klin (32) ima poligonalni, poželjno kvadratni presjek.
The herbicide combinations of the instant application as well as their use as described in the instant application are not disclosed in WO 00/08938 A1 . 
Herbicidne kombinacije ove prijave kao i njihova primjena kao što je opisano u ovoj prijavi nisu navedeni u WO 00/08938 A1.
<400> 66 A fusion protein comprising (i) an immunoglobulin molecule that is not capable of specific binding to an antigen and (ii) two mutant interleukin-2 (IL-2) molecules comprising an amino acid mutation that reduces affinity of the mutant IL-2 molecule to the intermediate affinity IL-2 receptor, as compared to a wild-type IL-2 molecule, wherein said mutant IL-2 molecules comprise the sequence of SEQ ID NO: 58. 
Fuzijski protein, naznačen time, da obuhvaća(i) molekulu imunoglobulina koja nije sposobna za specifično vezanje na antigen i (fi) dvije molekule mutantskog interleukina-2 (IL-2) koje obuhvaćaju mutaciju aminokiseline koja smanjuje afinitet mutantske IIL-2 molekule na srednji afinitet IL-2 receptora, u usporedbi s divljim tipom IL-2 molekule, pri čemu spomenute mutantske molekule IL-2 obuhvaćaju slijed SEQ ID NO; 58.
The safety helmet or headpiece of claim 1, wherein the light source is configured to be automatically activated when there is a sudden change of direction experienced by the wearer, such as if the wearer falls from an upright position to a lying position at a speed which is not normally experienced in carrying out relevant activities. 
Sigurnosna kaciga ili naglavni dio (10, 24, 42, 50) prema zahtjevu 1, naznačena time da je izvor svjetlosti (14, 20, 40, 52) konfiguriran da se automatski aktivira kada dođe do iznenadne promjene smjera do kojeg dolazi nositelj, pri čemu promjena smjera je pri brzini koje se obično ne doživljava kod provođenja odgovarajućih aktivnosti.
it has an amount of G0 structures on the total carbohydrate structures or on the carbohydrate structures at one particular glycosylation site of the protein molecule of said protein molecules in said protein molecule composition which is at least 5% lower compared to the same amount of protein molecules in at least one protein molecule composition of the same protein molecule isolated from ATCC No. 
- sadrži količinu fukoze na ukupnim ugljikohidratnim strukturama ili na ugljikohidratnim strukturama na nekom određenom mjestu glikoziliranja u molekuli protutijela kod navedenih molekula protutijela u navedenom pripravku s molekulom protutijela koja je najmanje 5% manja u usporedbi s istom količinom molekula protutijela u pripravku s najmanje jednom molekulom protutijela za istu molekula protutijela izoliranu iz ATCC No.
a sequence consisting of SEQ ID No. 1 
sekvence koja se sastoji od SEQ ID br. 2 i
Such modifications are intended to fall within the scope of the appended claims. Neramexane or a pharmaceutically acceptable salt thereof for use in the treatment or the prevention of tinnitus associated with hearing loss or mild hearing loss. 
PATENTNI ZAHTJEVI Nerameksan ili njegova farmaceutski prihvatljiva sol za uporabu kod liječenja ili prevencije tinitusa, naznačen time da se liječenje provodi unutar tri do dvanaest mjeseci od početka tinitusa (subakutni tinitus).
Ingredient in the present 
Sastojak u ovom izumu
A process for testing whether a sample contains an undesirable oxidation decomposition products of N-ethyl-N-phenyl-1,2,-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide which comprises determining whether the sample contains a compound having the structure: An isolated compound having the structure: 
Postupak za ispitivanje da li uzorak sadrži nepoželjni produkt oksidacijskog raspadanja N-etil-N-fenil-1,2-dihidro- 4-hidroksi-5-kloro-1-metil-2-oksokinolin-3-karboksamida, naznačen time, da obuhvaća određivanje, da li uzorak sadrži spoj koji ima sljedeću strukturu:
The sweetener composition comprises a high intensity sweetener, of which examples are listed in table 9, and, optionally, a low intensity sweetener. 
Sastavina sladila sadržava sladilo velike slatkoće, primjeri kojega su navedeni u Tablici 9, i opcijski, sladilo male slatkoće.
The method according to claim 6, wherein said arrangement of technical installations further comprises arranging a water-based heating system, a cooling system, and/or a sprinkler system. 
Postupak sukladno zahtjevu 6, pri čemu navedena organizacija tehničkih instalacija nadalje sadrži organiziranje sustava zagrijavanja temeljenog na vodi, sustava hlađenja, i/ili sustava prskalica.
The liquefied gas treatment method according to claim 1, wherein, in the ballast condition, the BOG generated in the cargo tank (1;11) is supplied as fuel to one of the main engine and the sub engine through the compressor line (140;L1). 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 1, naznačen time što se BOG, koji se ukapljuje izmjenjivačem topline (21), te dekomprimira elementom za dekomprimiranje (22), vraća u spremnik za teret (1;11).
a vaccine booster composition comprising 1 mg of the peptide having the amino acid sequence of SEQ ID NO:2, and 0.125 or 0.250 mg of human granulocyte-macrophage colony stimulating factor (GM-CSF) as an adjuvant, wherein the vaccine booster composition is formulated for administration by injection, preferably intradermal injection, every six months after the primary immunization schedule is complete. 
(1i) pripravak booster cjepiva koji sadrži 1 mg peptida koji sadrži sekvencu amino kiseline SEQ ID NO:2, 1 0.125 ili 0.250 mg humanog stimulirajućeg faktora kolonije granulocita/makrofaga (GM-CSF) kao adjuvanta, pri čemu je pripravak booster cjepiva formuliran za davanje pomoću injekcije, poželjno intradermalne injekcije, svakih šest mjeseci nakon završetka primarne imunizacije.
The method of claim 9, wherein the calcium-based sorbent is selected from the group consisting of calcium carbonate, calcium oxide, calcium hydroxide, calcium magnesium acetate (CaMg2(CH3COO)6), calcium bromide, dolomite (CaCO3. MgO), and combinations thereof. 
Sirovina za gorivo u skladu s patentnim zahtjevom 1, naznačena time, da je sorbens na bazi kalcija odabran iz skupine koju čine kalcijev hidroksid, kalcijev oksid, kalcijev bromid, kalcijev karbonat, dolomit, kalcij magnezijev acetat i njihove kombinacije.
The method of claim 2, wherein R45 is selected from the group consisting of —H, —OH, methoxy and ethoxy. 
Spoj prema zahtjevu 29, pri čemu je Rus izabran iz skupine koju čine -H, OH, metoksi i etoksi.
In another aspect, the composition of the invention comprises compounds of Formula (IV): 
Spoj bilo kojeg od patentnih zahtjeva 1 do 4, koje ima formulu (IV):
The wet granulated pharmaceutical composition according to one or more of the preceding claims 1 to 5, wherein a) said composition also contains at least one active drug in addition to Candesartan cilexetil. 
Vlažno granulirani farmaceutski pripravak u skladu s patentnim zahtjevom 5 ili 6, naznačen time što navedeni pripravak također sadrži najmanje jedan aktivni lijek uz kandesartan-cileksetil.
Composition of Tablet 
Sastav tablete
The plant of claim 14, wherein said plant is selected from the group consisting of maize, sorghum, wheat, sunflower, tomato, crucifers, peppers, potato, cotton, rice, soybean, sugarbeet, sugarcane, tobacco, barley, and oilseed rape. 
Biljka iz patentnog zahtjeva 11, naznačena time, da je navedena biljka odabrana iz skupine koju čine kukuruz, sirak, pšenica, suncokret, rajčica, zeljarice, paprike, krumpir, pamuk, riža, soja, šećerna repa, šećerna trska, duhan, ječam i uljana repica.
The sustained release composition of any one of claims 1 to 5, which is in the form of microparticles. 
Oblik za produljeno oslobađanje prema bilo kojem od zahtjeva 1 do koji je u obliku mikročestica.
A compound of formula (I) according to claim 1 for use in therapy. 
(D 2. < Spoj formule (I) prema zahtjevu 1 naznačena time za se koristi kod terapije.
The solution was concentrated and the residue was triturated with methanol. 
Otopina je koncentrirana i ostatak je trituriran metanolom.
In order to prove the effectivity of the pharmaceutical combination of the invention the following experiments were carried out: 
Da bi se dokazalo učinkovitost farmaceutske kombinacije prema izumu, provedeni su slijedeći pokusi: